NPKYY yields 3.96% · PFE yields 6.13%● Live data
📍 NPKYY pulled ahead of the other in Year 1
Combined, NPKYY + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of NPKYY + PFE for your $10,000?
Nippon Kayaku Co., Ltd., together with its subsidiaries, develops, manufactures, and sells functional chemicals, pharmaceuticals, safety systems, and agrochemicals and other products in Japan and internationally. The company's Functional and Chemical Business segment offers functional materials, such as epoxy resins, UV-curable resins, sealants for LCD and LED, maleimide resins, photoresists and insulating materials for micro electromechanical systems, and cleaning agents and chemicals. This segment also provides color materials, including inkjet colorants, dyes for textiles and papers, and materials for thermal paper; catalysts for the production of acrylic and methacrylic acid; and polarizing films, inorganic polarizers, liquid crystal display components and projector parts, and components for x-ray analysis. Its Pharmaceuticals Business segment offers anti-cancer and cancer-related drugs, biosimilars, generic drugs, interventional radiology products, cardiovascular drugs, bulk drugs and intermediates of pharmaceuticals, and drugs for diagnosing cancer, as well as GlycoMark, a product as a marker of blood sugar control used for diabetes. The company's Safety Systems Business segment provides airbag inflators, micro gas generators for seatbelt pretensioners, and squibs. Its Agrochemicals Business segment offers agricultural insecticides, herbicides, soil fumigants, and insanitary insecticides. The company also engages in real estate leasing services. The company was formerly known as Nihon Kayaku Seizou Co., Ltd. and changed its name to Nippon Kayaku Co., Ltd. in 1945. Nippon Kayaku Co., Ltd. was incorporated in 1916 and is headquartered in Tokyo, Japan.
Full NPKYY Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.